Sugi Predict

Sugi Predict / Targets / SLC13A2

SLC13A2

Solute carrier family 13 member 2 · Q13183 · SLC13A2 on Sugi Atlas →

45 patent compounds predicted against SLC13A2, 10 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30315756 SCHEMBL30315756 1.00 1/20
SCHEMBL12093547 SCHEMBL12093547 0.51 1/20
SCHEMBL5780686 SCHEMBL5780686 0.50 1/20
SCHEMBL5780868 SCHEMBL5780868 0.50 1/20
Citric Acid Citric Acid (SCHEMBL28101391) 0.47 1/20
SCHEMBL32689790 SCHEMBL32689790 0.46 1/20
Citric Acid Citric Acid (SCHEMBL2237856) 0.41 1/20
SCHEMBL19705861 SCHEMBL19705861 0.41 1/20
Citric Acid Citric Acid (SCHEMBL27851185) 0.41 1/20
Citric Acid Citric Acid (SCHEMBL5345353) 0.40 1/20

Clinical trials — most relevant to SLC13A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Age on the Renal Clearance of Adefovir PHASE4WITHDRAWN
Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder PHASE1/PHASE2NOT_YET_RECRUITING
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops PHASE2UNKNOWN
Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. PHASE2COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors PHASE1RECRUITING
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
SLC13A5 Deficiency Natural History Study - Remote Only nanENROLLING_BY_INVITATION
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors nanUNKNOWN
Gyrate Atrophy Ocular and Systemic Study nanACTIVE_NOT_RECRUITING
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population nanCOMPLETED
Genetic Variants and Iron Absorption nanCOMPLETED
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy nanCOMPLETED
Impact of Genetics on Metformin Pharmacokinetics nanCOMPLETED
Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population nanCOMPLETED
Genetically Guided Statin Therapy nanCOMPLETED
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders nanUNKNOWN
Register for Patients With Thyroid Hormone Resistance. nanRECRUITING
Oxalate and Citrate nanRECRUITING
Choroid Plexus Dysfunction in Neurological Diseases nanRECRUITING
Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin nanCOMPLETED
Role of the ATP7A Transporter in Ovarian Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC13A2 binder may also engage these)

ProteinNameSimilarity
Q9ES88 — 1.000 Q9ES88 →
Q28615 — 1.000 Q28615 →
P70545 — 1.000 P70545 →
Q67BT3 — 0.997 Q67BT3 →
Q9JHI4 — 0.996 Q9JHI4 →
Q91Y63 — 0.991 Q91Y63 →
Q9UKG4 — 0.990 Q9UKG4 →
Q07782 — 0.990 Q07782 →
Q9BZW2 — 0.987 Q9BZW2 →
Q8CJ44 — 0.987 Q8CJ44 →
SLC13A5 Na(+)/citrate cotransporter 0.986 landscape →
Q9Z0Z5 — 0.986 Q9Z0Z5 →
SLC13A3 Na(+)/dicarboxylate cotransporter 3 0.982 landscape →
Q93655 — 0.980 Q93655 →
Q21339 — 0.979 Q21339 →
P46556 — 0.975 P46556 →
Q9VVT2 — 0.973 Q9VVT2 →
SLC5A11 Sodium/myo-inositol cotransporter 2 0.969 landscape →
P58743 — 0.967 P58743 →
P32739 — 0.967 P32739 →
Q3ZMH1 — 0.965 Q3ZMH1 →
Q3ZC26 — 0.964 Q3ZC26 →
Q8LG88 — 0.964 Q8LG88 →
Q9VDQ0 — 0.963 Q9VDQ0 →
Q9EPH0 — 0.962 Q9EPH0 →
Q25605 — 0.962 Q25605 →
Q2M3M2 — 0.962 Q2M3M2 →
Q5SWY8 — 0.961 Q5SWY8 →
Q22682 — 0.961 Q22682 →
Q9JKQ2 — 0.961 Q9JKQ2 →